These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 23521050)

  • 1. Enhanced detection of hepatitis B virus in Hong Kong blood donors after introduction of a more sensitive transcription-mediated amplification assay.
    Tsoi WC; Lelie N; Lin CK
    Transfusion; 2013 Oct; 53(10 Pt 2):2477-88. PubMed ID: 23521050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood donation screening for hepatitis B virus markers in the era of nucleic acid testing: are all tests of value?
    Stramer SL; Zou S; Notari EP; Foster GA; Krysztof DE; Musavi F; Dodd RY
    Transfusion; 2012 Feb; 52(2):440-6. PubMed ID: 21810101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B virus testing by minipool nucleic acid testing: does it improve blood safety?
    Stramer SL; Notari EP; Krysztof DE; Dodd RY
    Transfusion; 2013 Oct; 53(10 Pt 2):2449-58. PubMed ID: 23607261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Head-to-head comparison of two transcription-mediated amplification assay versions for detection of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus Type 1 in blood donors.
    Grabarczyk P; van Drimmelen H; Kopacz A; Gdowska J; Liszewski G; Piotrowski D; Górska J; Kuśmierczyk J; Candotti D; Lętowska M; Lelie N; Brojer E
    Transfusion; 2013 Oct; 53(10 Pt 2):2512-24. PubMed ID: 23590145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis of triplex nucleic acid test assays in United States blood donors.
    Stramer SL; Krysztof DE; Brodsky JP; Fickett TA; Reynolds B; Dodd RY; Kleinman SH
    Transfusion; 2013 Oct; 53(10 Pt 2):2525-37. PubMed ID: 23550838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity of individual-donation and minipool nucleic acid amplification test options in detecting window period and occult hepatitis B virus infections.
    Vermeulen M; Coleman C; Mitchel J; Reddy R; van Drimmelen H; Ficket T; Lelie N
    Transfusion; 2013 Oct; 53(10 Pt 2):2459-66. PubMed ID: 23621791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reassessment of hepatitis B virus window periods for two transcription-mediated amplification assays using screening data of South African blood donors.
    Vermeulen M; van Drimmelen H; Coleman C; Sykes W; Reddy R; Busch M; Kleinman S; Lelie N
    Transfusion; 2019 Sep; 59(9):2922-2930. PubMed ID: 31265759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of hepatitis B virus (HBV) DNA screening and characterization of acute and occult HBV infections among blood donors from Madrid, Spain.
    González R; Torres P; Castro E; Barbolla L; Candotti D; Koppelman M; Zaaijer HL; Lelie N; Allain JP; Echevarría JM
    Transfusion; 2010 Jan; 50(1):221-30. PubMed ID: 19682332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of the risk of transfusion-transmitted viral infection by nucleic acid amplification testing in the Western Cape of South Africa: a 5-year review.
    Cable R; Lelie N; Bird A
    Vox Sang; 2013 Feb; 104(2):93-9. PubMed ID: 22924987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa.
    Vermeulen M; Lelie N; Sykes W; Crookes R; Swanevelder J; Gaggia L; Le Roux M; Kuun E; Gulube S; Reddy R
    Transfusion; 2009 Jun; 49(6):1115-25. PubMed ID: 19309474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
    Busch MP
    Transfus Clin Biol; 2004 Feb; 11(1):26-32. PubMed ID: 14980546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mathematical approach to estimate the efficacy of individual-donation and minipool nucleic acid amplification test options in preventing transmission risk by window period and occult hepatitis B virus infections.
    Vermeulen M; van Drimmelen H; Coleman C; Mitchel J; Reddy R; Lelie N
    Transfusion; 2014 Oct; 54(10):2496-504. PubMed ID: 24749834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of individual-donation and minipool testing to detect low-level hepatitis B virus DNA in Taiwan.
    Yang MH; Li L; Hung YS; Hung CS; Allain JP; Lin KS; Tsai SJ
    Transfusion; 2010 Jan; 50(1):65-74. PubMed ID: 19709394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity comparison of two Food and Drug Administration-licensed, triplex nucleic acid test automated assays for hepatitis B virus DNA detection and associated projections of United States yield.
    Stramer SL; Krysztof DE; Brodsky JP; Fickett TA; Reynolds B; Phikulsod S; Oota S; Lin M; Saldanha J; Kleinman SH
    Transfusion; 2011 Sep; 51(9):2012-22. PubMed ID: 21896033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity of hepatitis B virus DNA transcription-mediated amplification testing in hepatitis B surface antigen-positive blood donations.
    Bouchardeau F; Girault A; Razer A; Servant-Delmas A; Mercier M; Laperche S
    Transfusion; 2006 Dec; 46(12):2047-52. PubMed ID: 17176315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus.
    Li L; Chen PJ; Chen MH; Chak KF; Lin KS; Tsai SJ
    Transfusion; 2008 Jun; 48(6):1198-206. PubMed ID: 18422856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of different categories of hepatitis B virus (HBV) infection in a multi-regional study comparing the clinical sensitivity of hepatitis B surface antigen and HBV-DNA testing.
    Lelie N; Bruhn R; Busch M; Vermeulen M; Tsoi WC; Kleinman S;
    Transfusion; 2017 Jan; 57(1):24-35. PubMed ID: 27673757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program.
    Satake M; Taira R; Yugi H; Hino S; Kanemitsu K; Ikeda H; Tadokoro K
    Transfusion; 2007 Jul; 47(7):1197-205. PubMed ID: 17581154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy.
    Kuhns MC; Kleinman SH; McNamara AL; Rawal B; Glynn S; Busch MP;
    Transfusion; 2004 Sep; 44(9):1332-9. PubMed ID: 15318857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of improved hepatitis B surface antigen detection limits with hepatitis B virus DNA nucleic acid test yield in blood donations.
    Martin LA; Stramer SL; Kuhns MC; Schlauder GG
    Transfusion; 2012 Oct; 52(10):2201-8. PubMed ID: 22321072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.